$ADMP News
Last published 3y ago
- 3y agoADMPAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic FocusGlobeNewswireSAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals
- 3y agoADMPAdamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30,
- 3y agoADMPAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingGlobeNewswireSAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with
- 3y agoADMPAdamis Pharmaceuticals Announces Pricing of $8.0 Million Public OfferingGlobeNewswireSAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a
- 3y agoADMPAdamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid ExpertGlobeNewswireSAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research
- 3y agoADMPAdamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use DisorderGlobeNewswireSAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals
- 3y agoADMPAdamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose PreventionGlobeNewswireSAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is
- 3y agoADMPAdamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsGlobeNewswireDMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined companyCombined company will have commercial products and a library of development candidates, including two clinical stage programsDPI-125,
- 3y agoADMPAdamis Pharmaceuticals Announces Reverse Stock SplitGlobeNewswireSAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its
- 3y agoADMPAdamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoADMPAdamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate UpdateGlobeNewswireSAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various
- 3y agoADMPAdamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including
- 3y agoADMPAdamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate UpdateGlobeNewswireSAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various
- 3y agoADMPAdamis Pharmaceuticals Announces $3.0 Million Registered Direct OfferingGlobeNewswireSAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various
- 3y agoADMPAdamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of MergerGlobeNewswireCombined company will have commercial products and a library of development candidates, two of which are clinical stageWill be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhDLead development program
- 3y agoADMPNasdaq Grants Adamis Pharmaceuticals' Request for Extension to Comply with Continued Listing RequirementsGlobeNewswireSAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various
- 3y agoADMPAdamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various
- 4y agoADMPAdamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate UpdateGlobeNewswireSAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
- 4y agoADMPAdamis Announces Review of Strategic AlternativesGlobeNewswireSAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid ov
- 4y agoADMPAdamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk SubjectsGlobeNewswireInterim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Independent Data Safety Monitoring Board recommends h
- 4y agoADMPAdamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk SubjectsGlobeNewswireThe clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmace
- 4y agoADMPAdamis Pharmaceuticals Announces Results of Annual Meeting of StockholdersGlobeNewswireSAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that its 2022 Annual Meeting of Stockholders ("Annual Meeting") was convened, as scheduled. At the Annual Meeting, all items of business were
- 4y agoADMPAdamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, o
- 4y agoADMPAdamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate UpdateGlobeNewswireSAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today annou
- 4y agoADMPLeading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals' Stockholders Vote FOR Critical Proposals at Upcoming Annual MeetingGlobeNewswireISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on August 11, 2022 SAN DIEGO, July 29, 2022 (GLOBE
- 4y agoADMPAdamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19GlobeNewswireSAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided an update on the Company's ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19. The
- 4y agoADMPAdamis Pharmaceuticals Issues Letter to StockholdersGlobeNewswireSAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the
- 4y agoADMPAdamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19GlobeNewswireSAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today anno
- 4y agoADMPAdamis Appoints Vickie Reed to Board of DirectorsGlobeNewswireSAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Vickie Reed as a new director and member of the company's board of directors. Richard Williams, Chairman of the Board, c
- 4y agoADMPAdamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and GrowthGlobeNewswireDavid J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP
- 4y agoADMPAdamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announ
- 4y agoADMPAdamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business UpdateGlobeNewswireSAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announ
- 4y agoADMPAdamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today anno
- 4y agoADMPUS WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone ProductGlobeNewswireLOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), today announced the U.S. launch and availability of ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL.
- 4y agoADMPAdamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business UpdateGlobeNewswireSAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today anno
- 4y agoADMPAdamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster ModelGlobeNewswireSAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenge
- 4y agoADMPAdamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing DefectGlobeNewswireSAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes
- 4y agoADMPAdamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19GlobeNewswireSAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for
- 4y agoADMPAdamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the BoardGlobeNewswireSAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. "Dick has provided almost eight years of strategic leadership and comm
- 4y agoADMPAdamis Pharmaceuticals' Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment ExpectationsGlobeNewswireSAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo controlled Phase 2/3 trial for Tempol for the treatment of COV
- 4y agoADMPAdamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid ov
- 4y agoADMPAdamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19GlobeNewswireSAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company's ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Dat
- 4y agoADMPBITFDIDIHOOD+1Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?PR NewswireNEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP.
- 4y agoADMPAdamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19GlobeNewswireSAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVI
- 4y agoADMPAdamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™GlobeNewswireSAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company'
- 4y agoADMPAdamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing RequirementsGlobeNewswireSAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today annou
- 4y agoADMPAdamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today annou
- 4y agoADMPAdamis Pharmaceuticals Schedules Financial Results Conference Call and Business UpdateGlobeNewswireSAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today annou
- 5y agoADMPAVIRBTUIO+1Thinking about buying stock in Progenity, Atea Pharmaceuticals, Peabody Energy, Adamis Pharmaceuticals, or Ion Geophysical?PR NewswireNEW YORK, Oct. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PROG, AVIR, BTU, ADMP, and IO. To
- 5y agoADMPINMIOOYST+1Thinking about buying stock in Ion Geophysical, Valneva SE, Adamis Pharmaceuticals, Oyster Point Pharma, or InMed Pharmaceuticals?PR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, VALN, ADMP, OYST, and INM. To